

**AKUMS DRUGS & PHARMACEUTICALS LIMITED**

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/18

October 9, 2024

**To,**  
**The Listing Department**  
**National Stock Exchange of India Ltd**  
**Exchange Plaza, C-1, Block G,**  
**Bandra Kurla Complex,**  
**Bandra (E),**  
**Mumbai - 400 051**

**To,**  
**The Listing Department**  
**BSE Limited**  
**25th Floor, New Trading Ring,**  
**Rotunda Building, Phiroze**  
**Jeejeebhoy Towers, Dalal**  
**Street, Fort, Mumbai - 400 001**

Symbol: AKUMS

Scrip Code: 544222

**Sub: Intimation of revision / upgrade in Credit Rating under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Respected Sir/Mam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the details of the revision / upgrade in credit rating issued by ICRA Limited (Credit Rating Agency) vide its Letter dated October 9, 2024.

<b>Name of the company</b>	<b>Credit Rating Agency</b>	<b>Type of Credit rating</b>	<b>Existing</b>	<b>Revision / Upgrade</b>
Akums Drugs and Pharmaceuticals Limited	ICRA Limited	Long Term - Fund based Working Capital Facilities	AA-(Stable)	AA (Stable)

The report from the credit rating agency is enclosed.


This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Digitally signed by  
DHARAMVIR  
MALIK  
Date: 2024.10.09  
17:02:33 +05'30'

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



**ICRA/Akums Drugs & Pharmaceuticals Limited/09102024/1**

**Date: October 09, 2024**

**Mr. Sumeet Sood**  
Chief Financial Officer,  
Akums Drugs & Pharmaceuticals Limited,  
304, Mohan Place,  
L.S.C. Block C,  
Saraswati Vihar,  
Delhi – 110034

**Dear Sir,**

**Re: ICRA's Credit Rating for below mentioned Instruments of Akums Drugs & Pharmaceuticals Limited**

As per the Rating Agreement/Statement of Work executed with ICRA Limited, ICRA's Rating Committee has taken the following rating actions for the mentioned instruments of your company.

<b>Instrument</b>	<b>Rated Amount (Rs. crore)</b>	<b>Rating Action<sup>1</sup></b>
Long term-fund based working capital facilities	50.00	[ICRA]AA(Stable); Upgraded from [ICRA]AA-(Stable)
Unallocated limits	75.00	[ICRA]AA (Stable)/ [ICRA]A1+; LT rating upgraded from [ICRA]AA- (Stable) & ST rating reaffirmed
Short term-non fund based working capital limits	10.00	[ICRA]A1+; Reaffirmed
Long term / short term-fund based/non fund based limits	195.00	[ICRA]AA (Stable)/ [ICRA]A1+; LT rating upgraded from [ICRA]AA- (Stable) & ST rating reaffirmed
<b>Total</b>	<b>330.00</b>	

The aforesaid rating(s) will become due for surveillance within one year from the date of rating communication letter. However, ICRA reserves the right to review and/or, revise the above rating(s) at any time based on new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the rating(s). Therefore, request the lenders and investors to visit ICRA website at [www.icra.in](http://www.icra.in) for latest rating(s) of the company.

The rating(s) are specific to the terms and conditions of the instruments as indicated to us by you, and any change in the terms or size of the same would require a review of the rating(s) by us. In case there is any change in the terms and conditions or the size of the rated instrument, the same must be brought to our notice before the instrument is used by you. In the event such changes occur after the rating(s) have been assigned by us and their use has been confirmed by you, the rating(s) would be subject to our review, following which there could be a change in the rating(s) previously assigned. Notwithstanding the foregoing, any change in the over-all limit of the instrument from that specified in this letter, would constitute an enhancement that would not be covered by or under the said Rating Agreement.

The rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated instrument availed/issued by your company.

You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded.

<sup>1</sup> Complete definitions of the ratings assigned are available at [www.icra.in](http://www.icra.in).

We look forward to your communication and assure you of our best services.

With kind regards,  
Yours sincerely,  
For ICRA Limited

**SRI KUMAR KRISHNAMURTHY** Digitally signed by SRI KUMAR  
KRISHNAMURTHY  
Date: 2024.10.09 13:54:41 +05'30'

Srikumar Krishnamurthy  
Senior Vice President & Co group Head  
ksrikumar@icraindia.com

**Annexure**

Details of Bank Limits Rated by ICRA (Rated on Long-Term Scale)	Amount (Rs. crore)	Rating	Rating Assigned On
	<b>Fund based limits</b>		
State Bank of India	50.00	[ICRA]AA(Stable)	September 27, 2024
<b>Total</b>	<b>50.00</b>		

Details of Bank Limits Rated by ICRA (Rated on Short-Term Scale)	Amount (Rs. crore)	Rating	Rating Assigned On
	<b>Non-fund based limits</b>		
State Bank of India	10.00	[ICRA]A1+	September 27, 2024
<b>Total</b>	<b>10.00</b>		

Details of Bank Limits Rated by ICRA (Rated on Long-Term/Short-Term Scale)	Amount (Rs. crore)	Rating	Rating Assigned On
	<b>Fund based/ non-fund based limits</b>		
Citi Bank	50.00	[ICRA]AA(Stable)/ [ICRA]A1+	September 27, 2024
HSBC Bank	25.00	[ICRA]AA(Stable)/ [ICRA]A1+	September 27, 2024
HDFC Bank	60.00	[ICRA]AA(Stable)/ [ICRA]A1+	September 27, 2024
Yes Bank	60.00	[ICRA]AA(Stable)/ [ICRA]A1+	September 27, 2024
Unallocated limits	75.00	[ICRA]AA(Stable)/ [ICRA]A1+	September 27, 2024
<b>Total</b>	<b>270.00</b>		